Adapting the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for Use in Post-Authorisation Safety Studies Using US Data.

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Sarah Ruth Hoffman, Geetika Kalloo, Stephan Lanes, Aziza Jamal-Allial, Todd Sponholtz, Corinne Brooks, Maria Guzman, Maria I Van Rompay, Oluwadamilola Onasanya, Vincent J Willey, Erica Foster, Nadia Messeh, Jill Layton, Dawn Ponist, Maryline L E Noan-Lainé, Krista Schroeder
{"title":"Adapting the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for Use in Post-Authorisation Safety Studies Using US Data.","authors":"Sarah Ruth Hoffman, Geetika Kalloo, Stephan Lanes, Aziza Jamal-Allial, Todd Sponholtz, Corinne Brooks, Maria Guzman, Maria I Van Rompay, Oluwadamilola Onasanya, Vincent J Willey, Erica Foster, Nadia Messeh, Jill Layton, Dawn Ponist, Maryline L E Noan-Lainé, Krista Schroeder","doi":"10.1002/pds.70109","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Many post-authorization safety studies focus on congenital malformations and rely on diagnosis codes found in US data sources. However, no authoritative standards exist for identifying and classifying malformations in these data. To address this, we translated an existing public health surveillance guide, the European Concerted Action on Congenital Anomalies and Twins (EUROCAT), into an ICD-10-CM code list for use in studies using US administrative healthcare data. The EUROCAT guide was selected for its decisive major or minor classification of each code. However, translation was required for use in US data sources since EUROCAT utilizes ICD-10-BPA which differs from ICD-10-CM (the coding system commonly encountered in US data sources).</p><p><strong>Methods: </strong>We mapped EUROCAT to ICD-10-CM. For each code, manual review was conducted by two or more researchers, and major/minor classification was based on code descriptions since some codes differed between coding systems.</p><p><strong>Results: </strong>A final code list was created, containing 916 ICD-10-CM codes for 744 major and 172 minor malformations. The code list contains ICD-10-CM codes, their corresponding descriptions, their major or minor classification and disease category according to EUROCAT, and variables indicating anomalies caused by genetic or infectious diseases unlikely attributable to a medication.</p><p><strong>Conclusions: </strong>We adapted the EUROCAT Guide 1.5 into an ICD-10-CM code list for use in pregnancy studies using US data sources. This list includes new ICD-10-CM codes available in 2024. As new ICD-10-CM codes become available, or as the EUROCAT Guide is updated, further updates to this list will be needed.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 2","pages":"e70109"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829207/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Many post-authorization safety studies focus on congenital malformations and rely on diagnosis codes found in US data sources. However, no authoritative standards exist for identifying and classifying malformations in these data. To address this, we translated an existing public health surveillance guide, the European Concerted Action on Congenital Anomalies and Twins (EUROCAT), into an ICD-10-CM code list for use in studies using US administrative healthcare data. The EUROCAT guide was selected for its decisive major or minor classification of each code. However, translation was required for use in US data sources since EUROCAT utilizes ICD-10-BPA which differs from ICD-10-CM (the coding system commonly encountered in US data sources).

Methods: We mapped EUROCAT to ICD-10-CM. For each code, manual review was conducted by two or more researchers, and major/minor classification was based on code descriptions since some codes differed between coding systems.

Results: A final code list was created, containing 916 ICD-10-CM codes for 744 major and 172 minor malformations. The code list contains ICD-10-CM codes, their corresponding descriptions, their major or minor classification and disease category according to EUROCAT, and variables indicating anomalies caused by genetic or infectious diseases unlikely attributable to a medication.

Conclusions: We adapted the EUROCAT Guide 1.5 into an ICD-10-CM code list for use in pregnancy studies using US data sources. This list includes new ICD-10-CM codes available in 2024. As new ICD-10-CM codes become available, or as the EUROCAT Guide is updated, further updates to this list will be needed.

修改欧洲先天性异常和双胞胎协调行动(EUROCAT)指南1.5,用于使用美国数据的授权后安全性研究。
目的:许多授权后安全性研究侧重于先天性畸形,并依赖于美国数据源中的诊断代码。然而,没有权威的标准来识别和分类这些数据中的畸形。为了解决这个问题,我们将现有的公共卫生监测指南《欧洲先天性异常和双胞胎协调行动》(EUROCAT)翻译成ICD-10-CM代码清单,以便在使用美国行政保健数据的研究中使用。选择EUROCAT指南是因为它对每个代码进行了决定性的主要或次要分类。然而,在美国数据源中使用需要翻译,因为EUROCAT使用的ICD-10-BPA不同于ICD-10-CM(美国数据源中常见的编码系统)。方法:将EUROCAT与ICD-10-CM进行映射。对于每个代码,由两个或两个以上的研究人员进行人工审查,并且由于编码系统之间的一些代码不同,因此主要/次要分类是基于代码描述的。结果:形成最终的ICD-10-CM编码表,包含744例严重畸形和172例轻微畸形的916例ICD-10-CM编码。代码清单包含ICD-10-CM代码、相应的描述、根据EUROCAT的主要或次要分类和疾病类别,以及表明不太可能归因于药物的遗传或传染病引起的异常的变量。结论:我们将EUROCAT指南1.5改编为ICD-10-CM代码清单,用于使用美国数据源的妊娠研究。该清单包括2024年可用的新的ICD-10-CM代码。随着新的ICD-10-CM代码的出现,或随着EUROCAT指南的更新,将需要进一步更新该清单。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
7.70%
发文量
173
审稿时长
3 months
期刊介绍: The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信